Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.51 |
| ▸ | G6PD | P11413 | 2/20 | 0.49 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.42 |
| ▸ | SHBG | P04278 | 2/20 | 0.42 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528644 | 1.00 | CYP19A1 (0.61) | CYP19A1CYP1B1G6PDHSD17B3GPBAR1 | |
| SCHEMBL4440828 | 1.00 | CYP19A1 (0.61) | CYP19A1CYP1B1G6PDHSD17B3GPBAR1 | |
| SCHEMBL5312818 | 1.00 | CYP19A1 (0.61) | CYP19A1CYP1B1G6PDHSD17B3GPBAR1 | |
| SCHEMBL503216 | 1.00 | CYP19A1 (0.61) | CYP19A1CYP1B1G6PDHSD17B3GPBAR1 | |
| SCHEMBL502993 | 0.86 | CYP19A1 (0.61) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL502992 | 0.86 | CYP19A1 (0.61) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL502481 | 0.85 | CYP19A1 (0.63) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL502482 | 0.85 | CYP19A1 (0.63) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL502634 | 0.85 | CYP19A1 (0.63) | CYP19A1G6PDHSD17B3GPBAR1LMNA | |
| SCHEMBL15094423 | 0.85 | CYP19A1 (0.63) | CYP19A1G6PDHSD17B3GPBAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408856-B2 | Topical steroidal formulations | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-08-09 | — | — | US | claimed |
| US-20130196959-A1 | TOPICAL STEROIDAL FORMULATIONS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2013-08-01 | — | — | US | claimed |
| US-20130064815-A1 | INDUCING APOPTOSIS IN QUIESCENT CELLS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | claimed |
| US-20100004217-A1 | TOPICAL STEROIDAL FORMULATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-07 | — | — | US | claimed |
| EP-0934745-B1 | Use of androsterone derivatives for inhibiting DNA binding of ap-1 and airway smooth muscle proliferation | CHARLOTTE MECKLENBURG HOSPITAL (US) | 2004-04-28 | — | — | EP | claimed |
| US-20040019026-A1 | Compounds useful for treating hypertriglyceridemia | BIOVIE INC. | 2004-01-29 | — | — | US | claimed |
| EP-1351971-A2 | COMPOUNDS USEFUL FOR TREATING HYPERTRIGLYCERIDEMIA | Aeson Therapeutics Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| WO-2002028880-A2 | COMPOUNDS USEFUL FOR TREATING HYPERTRIGLYCERIDEMIA | AESON THERAPEUTICS INC. (US) | 2002-04-11 | — | — | WO | claimed |
| EP-0934745-A1 | Use of androsterone derivatives for inhibiting DNA binding of ap-1 and airway smooth muscle proliferation | CHARLOTTE-MECKLENBURG HOSPITAL doing business as Carolinas Medical Center (US) | 1999-08-11 | — | — | EP | claimed |
| EP-2486924-B1 | Drugs and uses | NEURMEDIX INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-9408856-B2 | Topical steroidal formulations | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-08-09 | — | — | US | disclosed |
| US-9402853-B2 | Topical steroidal formulations | TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATION (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2303279-B1 | TOPICAL STEROIDAL FORMULATIONS | SCHWARTZ ARTHUR (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20150071904-A1 | COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA | TRUSTEES OF BOSTON UNIVERSITY | 2015-03-12 | — | — | US | disclosed |
| US-5696106-A | Steroids useful as anti-cancer and anti-obesity agents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| US-5656621-A | ADMINISTERING ANTIDIABETIC, ANTIAGING, ANTIHYPERCHOLESTROLEMIC, ANTIHYPERGLYCEMIC AGENT | RESEARCH CORPORATION TECH., INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5157031-A | Androsterone derivatives | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0246650-B1 | STEROIDS USEFUL AS ANTI-CANCER AND ANTI-OBESITY AGENTS, A THERAPEUTIC COMPOSITION CONTAINING THEM AND USE THEREOF FOR THE PREPARATION OF A THERAPEUTIC COMPOSITION | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-01-02 | — | — | EP | disclosed |
| US-4898694-A | 17-Hydroxy-steroids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 1990-02-06 | — | — | US | disclosed |
| EP-0246650-A1 | Steroids useful as anti-cancer and anti-obesity agents, a therapeutic composition containing them and use thereof for the preparation of a therapeutic composition | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1987-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004217-A1 | TOPICAL STEROIDAL FORMULATIONS | CYP17A1, HSD17B7, CYP11B1 | CYP19A1 34/4885CYP1B1 132/4885G6PD 2121/4885 |
| US-20040019026-A1 | Compounds useful for treating hypertriglyceridemia | PNLIP, LIPC, LIPA | CYP19A1 695/4885CYP1B1 1376/4885G6PD 199/4885 |
| US-20130196959-A1 | TOPICAL STEROIDAL FORMULATIONS | CYP17A1, HSD17B7, CYP11B1 | CYP19A1 34/4885CYP1B1 132/4885G6PD 2121/4885 |
| US-20150071904-A1 | COMPOSITIONS AND METHODS TO BOOST ENDOGENOUS ROS PRODUCTION FROM BACTERIA | ROS1, NOX4, CYBB | CYP19A1 2089/4885CYP1B1 937/4885G6PD 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.